CSF3 and neutropenia: The biosimilar recombinant human G-CSF (rhG-CSF), possessing a similar biological mechanism, has been successfully approved for application in reducing the risk and duration of chemotherapy-induced neutropenia and febrile neutropenia [12, 13].